アミロイドーシス:パイプラインレビュー2019下半期

【英語タイトル】Amyloidosis - Pipeline Review, H2 2019

Global Markets Directが出版した調査資料(GDATA9120309)・商品コード:GDATA9120309
・発行会社(調査会社):Global Markets Direct
・発行日:2019年11月
・ページ数:217
・レポート言語:英語
・レポート形式:PDF
・納品方法:Eメール(受注後24時間以内)
・調査対象地域:グローバル
・産業分野:製薬及び医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD2,000 ⇒換算¥214,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD4,000 ⇒換算¥428,000見積依頼/購入/質問フォーム
Enterprisewide Price(複数事業所内共有可)USD6,000 ⇒換算¥642,000見積依頼/購入/質問フォーム
販売価格オプションの説明
※お支払金額:換算金額(日本円)+消費税
※納期:即日〜2営業日(3日以上かかる場合は別途表記又はご連絡)
※お支払方法:納品日+5日以内に請求書を発行・郵送(請求書発行日より2ヶ月以内に銀行振込、振込先:三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能)
【レポートの概要】

Amyloidosis – Pipeline Review, H2 2019
Summary

Global Markets Direct’s latest Pharmaceutical and Healthcare disease pipeline guide Amyloidosis – Pipeline Review, H2 2019, provides an overview of the Amyloidosis (Metabolic Disorders) pipeline landscape.

Abnormal accumulation of amyloid protein in the tissues results in a group of diseases known as amyloidosis. It may affect the shape and functioning of the organ eventually leading to organ failure. Predisposing factors are misfolding of abnormal protein called the light chain and its subsequent deposition in the body. It may also occur as a result of dialysis. Symptoms include fatigue, chest pain, swelling and breathing problems. Amyloidosis can be managed by transplant and, medication such as diuretics and chemotherapy drugs.

Report Highlights

Global Markets Direct’s Pharmaceutical and Healthcare latest pipeline guide Amyloidosis – Pipeline Review, H2 2019, provides comprehensive information on the therapeutics under development for Amyloidosis (Metabolic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Amyloidosis (Metabolic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Amyloidosis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 2, 1, 3, 8, 5, 8 and 5 respectively. Similarly, the Universities portfolio in Phase III, Phase II, Preclinical and Discovery stages comprises 1, 1, 1 and 1 molecules, respectively.

Amyloidosis (Metabolic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Amyloidosis (Metabolic Disorders).
- The pipeline guide reviews pipeline therapeutics for Amyloidosis (Metabolic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Amyloidosis (Metabolic Disorders) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Amyloidosis (Metabolic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Amyloidosis (Metabolic Disorders)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Amyloidosis (Metabolic Disorders).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Amyloidosis (Metabolic Disorders) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

【レポートの目次】

Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Amyloidosis – Overview
Amyloidosis – Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Amyloidosis – Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Amyloidosis – Companies Involved in Therapeutics Development
Akcea Therapeutics Inc
Alnylam Pharmaceuticals Inc
Amgen Inc
BSIM Therapeutics SA
Celgene Corp
Chugai Pharmaceutical Co Ltd
Eidos Therapeutics Inc
Johnson & Johnson
Mabpharm Ltd
Neurimmune Holding AG
Oncopeptides AB
Pfizer Inc
Precision Biosciences Inc
Prothena Corp Plc
R Pharm
Regeneron Pharmaceuticals Inc
Spectrum Pharmaceuticals Inc
Amyloidosis – Drug Profiles
AKCEA-TTR-LRx – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BBP-265 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CAEL-101 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
canakinumab biosimilar – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
carfilzomib – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CLR-01 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
daratumumab – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
doxycycline hyclate – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
EDE-1307 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
eprodisate disodium – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Fusion Proteins to Inhibit ABPP, MAPT and NACP for Amyloidosis and Neurodegenerative Diseases – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Gene Therapy to Activate Transthyretin For Familial Amyloid Neuropathies – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Gene Therapy to Target CS1 for Metabolic Disorders and Oncology – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
inotersen sodium – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
melphalan – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
melphalan flufenamide hydrochloride – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclonal Antibody for Familial Amyloid Cardiomyopathy – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclonal Antibody to Target CD66b for Blood Cancer and Metabolic Disorders – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NI-006 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NPT-189 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NTLA-1001 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Oligonucleotides to Activate TTR for Amyloidosis – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
patisiran – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Peptides to Inhibit TTR for Familial Transthyretin Amyloidosis – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
pomalidomide – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PRX-004 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
RPH-104 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Activate ATF6 for Amyloidosis – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit Transthyretin Related Amyloid Protein for Familial Amyloidotic Cardiomyopathy – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit Transthyretin Related Amyloid Protein for Familial Amyloidotic Polyneuropathy – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
tafamidis meglumine – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
tocilizumab – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
tolcapone – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
VERU-111 – Drug Profile
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development for Amyloidosis, H2 2019
Number of Products under Development by Companies, H2 2019
Number of Products under Development by Companies, H2 2019 (Contd..1), H2 2019
Number of Products under Development by Universities/Institutes, H2 2019
Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019 (Contd..1), H2 2019
Products under Development by Companies, H2 2019 (Contd..2), H2 2019
Products under Development by Universities/Institutes, H2 2019
Number of Products by Stage and Target, H2 2019
Number of Products by Stage and Mechanism of Action, H2 2019
Number of Products by Stage and Route of Administration, H2 2019
Number of Products by Stage and Molecule Type, H2 2019
Amyloidosis - Pipeline by Akcea Therapeutics Inc, H2 2019
Amyloidosis - Pipeline by Alnylam Pharmaceuticals Inc, H2 2019
Amyloidosis - Pipeline by Amgen Inc, H2 2019
Amyloidosis - Pipeline by BSIM Therapeutics SA, H2 2019
Amyloidosis - Pipeline by Celgene Corp, H2 2019
Amyloidosis - Pipeline by Chugai Pharmaceutical Co Ltd, H2 2019
Amyloidosis - Pipeline by Eidos Therapeutics Inc, H2 2019
Amyloidosis - Pipeline by Johnson & Johnson, H2 2019
Amyloidosis - Pipeline by Mabpharm Ltd, H2 2019
Amyloidosis - Pipeline by Neurimmune Holding AG, H2 2019
Amyloidosis - Pipeline by Oncopeptides AB, H2 2019
Amyloidosis - Pipeline by Pfizer Inc, H2 2019
Amyloidosis - Pipeline by Precision Biosciences Inc, H2 2019
Amyloidosis - Pipeline by Prothena Corp Plc, H2 2019
Amyloidosis - Pipeline by R Pharm, H2 2019
Amyloidosis - Pipeline by Regeneron Pharmaceuticals Inc, H2 2019
Amyloidosis - Pipeline by Spectrum Pharmaceuticals Inc, H2 2019
Amyloidosis - Dormant Projects, H2 2019
Amyloidosis - Dormant Projects, H2 2019 (Contd..1), H2 2019
Amyloidosis - Discontinued Products, H2 2019

List of Figures
Number of Products under Development for Amyloidosis, H2 2019 10
Number of Products under Development by Companies, H2 2019 11
Number of Products under Development by Universities/Institutes, H2 2019 14
Number of Products by Top 10 Targets, H2 2019 19
Number of Products by Stage and Top 10 Targets, H2 2019 19
Number of Products by Top 10 Mechanism of Actions, H2 2019 21
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2019 21
Number of Products by Routes of Administration, H2 2019 23
Number of Products by Stage and Routes of Administration, H2 2019 23
Number of Products by Top 10 Molecule Types, H2 2019 25
Number of Products by Stage and Top 10 Molecule Types, H2 2019 25

【掲載企業】

Akcea Therapeutics Inc
Alnylam Pharmaceuticals Inc
Amgen Inc
BSIM Therapeutics SA
Celgene Corp
Chugai Pharmaceutical Co Ltd
Eidos Therapeutics Inc
Johnson & Johnson
Mabpharm Ltd
Neurimmune Holding AG
Oncopeptides AB
Pfizer Inc
Precision Biosciences Inc
Prothena Corp Plc
R Pharm
Regeneron Pharmaceuticals Inc
Spectrum Pharmaceuticals Inc

★調査レポート[アミロイドーシス:パイプラインレビュー2019下半期] (コード:GDATA9120309)販売に関する免責事項を必ずご確認ください。
★調査レポート[アミロイドーシス:パイプラインレビュー2019下半期]についてメールでお問い合わせ


◆H&Iグローバルリサーチのお客様(例)◆